June 19, 2018
Sanofi wraps up €3,9 billion acquisition of Ablynx
Sanofi and Ablynx have completed the acquisition, as Sanofi has acquired all outstanding shares, warrants and convertible bonds of Ablynx.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Ablynx
January 29, 2018
Sanofi buys Ablynx for €3,9 billion
Sanofi will buy Belgian Nanobody technology specialist Ablynx for €3.9 billion, it was announced Monday by both companies.
January 24, 2018
Ablynx opens door for new scientific boss
Belgian based drugmaker Ablynx has appointed Robert Friesen, PhD, as Chief Scientific Officer (CSO), who will begin his role in…
January 8, 2018
Novo Nordisk in Ablynx €2.6 Billion buy
Novo Nordisk on Monday confirmed proposing on December 22, 2017 to acquire Ablynx for €28.00 per share in cash and…
October 25, 2017
Ablynx prices $200M public offering, trades on NASDAQ
Belgian Ablynx on Wednesday announced the pricing of its initial U.S. public offering totaling $200 million, from 11,430,000 American Depositary…
October 16, 2017
Ablynx names leader for its newly established USA subsidiary
Ablynx has expanded in the USA, with a subsidiary company, Ablynx Inc., as it has appointed Daniel Schneider as the General…
July 26, 2017
Ablynx’s Nanobody Fast Track listed by the US FDA, third phase study report in 2017
Ablynx was granted Fast Track designation for caplacizumab, by the that the U.S. Food and Drug Administration (FDA). That’s the company’s first-in-class anti-von Willebrand factor (vWF) Nanobody developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
July 20, 2017
Ablynx, Sanofi in multimillion euros deal for treating inflammatory disease
Ablynx and Sanofi have made a deal for research collaboration and global exclusive licensing agreement related to Nanobody-based therapeutics for the treatment of various immune-mediated inflammatory diseases.
July 17, 2017
Ablynx to nominate new Independent Non-Executive Director
Ablynx has announced that Hilde Windels will be nominated as an Independent Non-Executive Director at the Company`s forthcoming Special General Meeting of its shareholders to be held on 18 August 2017.
February 9, 2017
Ablynx to present RA research data at CRA Annual Scientific Meeting
Ablynx will present additional data from the Phase IIb RA combination study of its anti-IL-6R Nanobody, vobarilizumab, at the Annual Scientific Meeting of the Canadian Rheumatology Association, being held from 8-11 February 2017 in Ottawa, Ontario (Canada).